142 related articles for article (PubMed ID: 17524950)
1. Complete regression of cutaneous B-cell lymphoma in a renal transplant patient after conversion from cyclosporin to sirolimus.
Mohsin N; Budruddin M; Kamble P; Khalil M; Pakkyarra A; Jha A; Mohammed E; Ahmed H; Ahmed J; Thomas S; Campistol JM; Daar A
Transplant Proc; 2007 May; 39(4):1267-71. PubMed ID: 17524950
[TBL] [Abstract][Full Text] [Related]
2. Mucosa-associated lymphoid tissue gastric lymphoma regression in a renal transplant patient after conversion of the immunosuppression to sirolimus: a case report.
Lasmar EP; Coelho LG; Lasmar MF; Lasmar LF; Lima PV; Nogueira AF
Transplant Proc; 2009 Apr; 41(3):959-61. PubMed ID: 19376398
[TBL] [Abstract][Full Text] [Related]
3. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies.
Boratyńska M; Watorek E; Smolska D; Patrzałek D; Klinger M
Transplant Proc; 2007 Nov; 39(9):2736-9. PubMed ID: 18021973
[TBL] [Abstract][Full Text] [Related]
4. Regression of post-transplant Kaposi's sarcoma using sirolimus.
Kolhe N; Mamode N; Van der Walt J; Pattison J
Int J Clin Pract; 2006 Nov; 60(11):1509-12. PubMed ID: 16787440
[TBL] [Abstract][Full Text] [Related]
5. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation.
Manuelli M; De Luca L; Iaria G; Tatangelo P; Sforza D; Perrone L; Bellini MI; Angelico R; Anselmo A; Tisone G
Transplant Proc; 2010 May; 42(4):1314-6. PubMed ID: 20534289
[TBL] [Abstract][Full Text] [Related]
6. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
[TBL] [Abstract][Full Text] [Related]
7. Complete regression of visceral Kaposi's sarcoma after conversion to sirolimus.
Mohsin N; Budruddin M; Pakkyara A; Darweesh A; Nayyer M; Amitabh J; Daar AS
Exp Clin Transplant; 2005 Dec; 3(2):366-9. PubMed ID: 16417445
[TBL] [Abstract][Full Text] [Related]
8. Primary intestinal posttransplant T-cell lymphoma.
Michael J; Greenstein S; Schechner R; Tellis V; Vasovic LV; Ratech H; Glicklich D
Transplantation; 2003 Jun; 75(12):2131-2. PubMed ID: 12829924
[TBL] [Abstract][Full Text] [Related]
9. Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia.
Fernández A; Marcén R; Pascual J; Galeano C; Ocaña J; Arellano EM; Alfaro C; Villafruela JJ; Burgos FJ; Ortuño J
Transplant Proc; 2006 Oct; 38(8):2453-5. PubMed ID: 17097965
[TBL] [Abstract][Full Text] [Related]
10. Conversion to sirolimus in posttransplant renal neoplasms.
Lopez V; Gutierrez C; Cabello M; Burgos D; Sola E; Gonzalez-Molina M
Transplant Proc; 2007 Sep; 39(7):2264-6. PubMed ID: 17889158
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of post-renal transplant gastric and pulmonary Kaposi's sarcoma with conversion to rapamycin treatment.
Charfi S; Krichen-Makni S; Yaich S; Makni H; Khabir A; Amouri A; Charfeddine K; Hachicha J; Sellami-Boudawara T
Saudi J Kidney Dis Transpl; 2007 Nov; 18(4):617-20. PubMed ID: 17951954
[TBL] [Abstract][Full Text] [Related]
13. Posttransplant cutaneous T-cell lymphoma: case reports and review of the association of calcineurin inhibitor use with posttransplant lymphoproliferative disease risk.
Pomerantz RG; Campbell LS; Jukic DM; Geskin LJ
Arch Dermatol; 2010 May; 146(5):513-6. PubMed ID: 20479299
[TBL] [Abstract][Full Text] [Related]
14. Resolution of sirolimus-induced pneumonitis after conversion to everolimus.
Rehm B; Keller F; Mayer J; Stracke S
Transplant Proc; 2006 Apr; 38(3):711-3. PubMed ID: 16647451
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
[TBL] [Abstract][Full Text] [Related]
16. Protocol conversion from a calcineurin inhibitor based therapy to sirolimus.
Oberbauer R
Transplantation; 2009 Apr; 87(8 Suppl):S7-10. PubMed ID: 19384186
[TBL] [Abstract][Full Text] [Related]
17. Case report: successful treatment of posttransplant lymphoproliferative disorder and quiescence of dermatomyositis with rituximab and sirolimus.
Kaposztas Z; Etheridge WB; Kahan BD
Transplant Proc; 2008 Jun; 40(5):1744-6. PubMed ID: 18589184
[TBL] [Abstract][Full Text] [Related]
18. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation: case reports.
Iaria G; Anselmo A; De Luca L; Manuelli M; Lucchesi C; Tariciotti L; Monaco A; Sforza D; Nigro F; Abruzzese E; Tisone G
Transplant Proc; 2007; 39(6):2036-7. PubMed ID: 17692685
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus used during pregnancy in a living related renal transplant recipient: a case report.
Chu SH; Liu KL; Chiang YJ; Wang HH; Lai PC
Transplant Proc; 2008 Sep; 40(7):2446-8. PubMed ID: 18790264
[TBL] [Abstract][Full Text] [Related]
20. Late conversion to everolimus complicated with necrotizing glomerulonephritis in a renal allograft recipient: case report.
Nowacka-Cieciura E; Perkowska-Ptasińska A; Sulikowska-Rowińska A; Cieciura T; Wazna E; Durlik M
Transplant Proc; 2009; 41(1):441-5. PubMed ID: 19249576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
